Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Jongseok Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review Article
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Cancer Res Treat. 2017;49(4):851-868.   Published online January 3, 2017
DOI: https://doi.org/10.4143/crt.2016.176
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress. Included studies aimed to prospectively evaluate the efficacy and safety of anti-angiogenic agents in advanced gastric or gastroesophageal junction cancer. Each trial investigated at least one of the following endpoints: overall survival, progression-free survival/time to progression, and/or objective response rate. Our search yielded 139 publications. Forty-two met the predefined inclusion criteria. Included studies reported outcomes with apatinib, axitinib, bevacizumab, orantinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, telatinib, and vandetanib. Second-line therapy with ramucirumab and third-line therapy with apatinib are the only anti-angiogenic agents so far shown to significantly improve survival of patients with advanced gastric cancer. Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.

Citations

Citations to this article as recorded by  
  • The Potential Impact of Renin–Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis
    Kaneez Fatima, Aayat Ellahi, Mariam Adil, Haider Kashif, Muhammad Uzair, Naela Ashraf, Mehak Barolia, Mujtaba Hyder, Areeba Nakhuda, Michelle Ayub, Sofia Jamil Butt, Ahmed Mustafa Rashid
    Journal of Cardiovascular Pharmacology.2025; 85(1): 35.     CrossRef
  • Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis
    Liang Wang, Juyuan Li, Huamin Chen
    Chemotherapy.2024; 69(1): 11.     CrossRef
  • Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
    Ujjawal Sharma, Bunty Sharma, Ambrish Mishra, Anidrisha Sahu, Darin M. Mathkor, Shafiul Haque, Deepika Raina, Seema Ramniwas, Madhu Gupta, Hardeep S. Tuli
    Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
  • Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway
    Huina Wang, Qingzhu Ding, Haihua zhou, Chuanjiang Huang, Guiyuan Liu, Xiaojun Zhao, Zhiyi Cheng, Xiaolan You
    Phytomedicine.2024; 134: 155962.     CrossRef
  • Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
    Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
    Cancer Medicine.2023; 12(7): 7784.     CrossRef
  • Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
    Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisu
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510
    Anica Högner, Salah‐Eddin Al‐Batran, Jens T. Siveke, Mario Lorenz, Prisca Bartels, Kirstin Breithaupt, Peter Malfertheiner, Nils Homann, Alexander Stein, Dietrich Gläser, Ingo Tamm, Axel Hinke, Arndt Vogel, Peter Thuss‐Patience
    International Journal of Cancer.2022; 150(6): 1007.     CrossRef
  • Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer
    Linyan Zhang, Simeng Qin, Liuyi Lu, Li Huang, Shan Li
    The International Journal of Biological Markers.2022; 37(1): 66.     CrossRef
  • Tumor vessel normalization and immunotherapy in gastric cancer
    Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy
    Yanling Ai, Ziyi Zhao, Hengyi Wang, Xiaomei Zhang, Weihan Qin, Yanlei Guo, Maoyuan Zhao, Jianyuan Tang, Xiao Ma, Jinhao Zeng
    Phytotherapy Research.2022; 36(9): 3371.     CrossRef
  • Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
    Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Cai Zhao, Xiangshun Kong, Yao Rong, Weida Zheng, Peng Yu, Yuou Teng
    RSC Advances.2022; 12(34): 21821.     CrossRef
  • Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
    Hardeep Singh Tuli, Ajay Kumar, Seema Ramniwas, Renuka Coudhary, Diwakar Aggarwal, Manoj Kumar, Ujjawal Sharma, Nidarshana Chaturvedi Parashar, Shafiul Haque, Katrin Sak
    Molecules.2022; 27(21): 7653.     CrossRef
  • Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis
    Yanjun Mi, Yongwen Li, Zhuo He, Donghan Chen, Qingqi Hong, Jun You
    Cancer Management and Research.2021; Volume 13: 899.     CrossRef
  • Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
    Shucheng Chen, Lan Yao
    Cancer Chemotherapy and Pharmacology.2021; 88(2): 323.     CrossRef
  • Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC
    Yuanyuan Ma, Xinyu Su, Xin Li, Xiaohui Zhi, Kan Jiang, Jianhong Xia, Hongliang Li, Chen Yan, Liqing Zhou
    Scientific Reports.2021;[Epub]     CrossRef
  • Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
    Xing Kang, En Xu, Xingzhou Wang, Lulu Qian, Zhi Yang, Heng Yu, Chao Wang, Chuanfu Ren, Yizhou Wang, Xiaofeng Lu, Xuefeng Xia, Wenxian Guan, Tong Qiao
    Cell Death & Disease.2021;[Epub]     CrossRef
  • A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
    Lin Li, Yuexian Li, Huawei Zou
    PeerJ.2021; 9: e12356.     CrossRef
  • Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
    Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hi
    Journal of Gastroenterology.2020; 55(6): 627.     CrossRef
  • The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
    Shahrzad S. Fard, Kioomars Saliminejad, Masoud Sotoudeh, Niloofar Soleimanifard, Shaghayegh Kouchaki, Mansour Yazdanbod, Habibollah Mahmoodzadeh, Ardeshir Ghavamzadeh, Reza Malekzadeh, Bahram Chahardouli, Kamran Alimoghaddam, Seyed H. Ghaffari
    Anti-Cancer Agents in Medicinal Chemistry.2020; 19(17): 2097.     CrossRef
  • Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
    Alessandro Rizzo, Veronica Mollica, Angela Dalia Ricci, Ilaria Maggio, Maria Massucci, Fabiola Lorena Rojas Limpe, Francesca Di Fabio, Andrea Ardizzoni
    Future Oncology.2020; 16(2): 4409.     CrossRef
  • S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma
    Chu Zhang, Guang-Mao Yu, Miao Zhang, Dong Liu
    Medicine.2020; 99(1): e18691.     CrossRef
  • An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
    Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianf
    Therapeutic Advances in Medical Oncology.2020;[Epub]     CrossRef
  • The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
    Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang, Xin Sun
    International Journal of Clinical Oncology.2020; 25(6): 1195.     CrossRef
  • Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
    Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He, Mingyan E
    Expert Review of Clinical Pharmacology.2020; 13(12): 1423.     CrossRef
  • Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature
    Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka, Masahito Shimizu
    Journal of Gastrointestinal Cancer.2019; 50(3): 556.     CrossRef
  • Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
    Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha, Peush Bajpai
    Journal of Gastrointestinal Cancer.2019; 50(4): 943.     CrossRef
  • Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
    Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, Alberto Russi, Federica Todino, Vincenzo Dadduzio, Francesca Bergamo, Alessandra Anna Prete, Sara Lonardi, Hans Prenen, Angelo Claudio Palozzo, Fotios Loupakis
    Drug Safety.2019; 42(2): 159.     CrossRef
  • VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
    Lian Lian, Xiang-Li Li, Meng-Dan Xu, Xian-Min Li, Meng-Yao Wu, Yan Zhang, Min Tao, Wei Li, Xiao-Ming Shen, Chong Zhou, Min Jiang
    BMC Cancer.2019;[Epub]     CrossRef
  • STUDY OF VEGF-A AND TGF-Β LEVELS IN BIOPTATES OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND MOUTH FLOOR MUCOSA IN POLYCHEMOTHERAPY WITH MONOCLONAL ANTIBODIES – CETUXIMAB
    O. I. Kit, E. M. Frantsiyants, I. V. Neskubina, L. Yu. Vladimirova, A. A. Lyanova, Yu. A. Pogorelova, E. V. Shalashnaya, M. A. Еngibaryan, Yu. S. Sidorenko
    Research and Practical Medicine Journal.2019; 6(3): 20.     CrossRef
  • Tumor progression-dependent angiogenesis in gastric cancer and its potential application
    Hsi-Lung Hsieh, Ming-Ming Tsai
    World Journal of Gastrointestinal Oncology.2019; 11(9): 686.     CrossRef
  • Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
    Guohui Liu, Chunbo Wang, Yunlong He, Mingyan E
    BMC Pharmacology and Toxicology.2019;[Epub]     CrossRef
  • N-methyl-N-nitro-N-nitrosoguanidine-mediated ING4 downregulation contributed to the angiogenesis of transformed human gastric epithelial cells
    Yansu Chen, Rui Fu, Mengdie Xu, Yefei Huang, Guixiang Sun, Lichun Xu
    Life Sciences.2018; 199: 179.     CrossRef
  • GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
    Keshuo Ding, Sheng Tan, Xing Huang, Xiaonan Wang, Xiaocan Li, Rong Fan, Yong Zhu, Peter E. Lobie, Wenbin Wang, Zhengsheng Wu
    Journal of Biological Chemistry.2018; 293(11): 3949.     CrossRef
  • Nanoparticles designed to regulate tumor microenvironment for cancer therapy
    Min Li, Fangrong Zhang, Yujie Su, Jianping Zhou, Wei Wang
    Life Sciences.2018; 201: 37.     CrossRef
  • Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
    Xiaodong Wang, Yu Liu, Yuwen Diao, Ningning Gao, Yanyan Wan, Jingjing Zhong, Huali Zheng, Zhulin Wang, Guangyi Jin
    Journal of Translational Medicine.2018;[Epub]     CrossRef
  • ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer
    In-Hwan Kim
    Annals of Surgical Oncology.2018; 25(S3): 749.     CrossRef
  • Identification of Bone Metastasis-associated Genes of Gastric Cancer by Genome-wide Transcriptional Profiling
    Mingzhe Lin, Xin Li, Haizhou Guo, Faxiang Ji, Linhan Ye, Xuemei Ma, Wen Cheng
    Current Bioinformatics.2018; 14(1): 62.     CrossRef
  • Antiangiogenic effects of oridonin
    Lili Tian, Kangjie Xie, Donglai Sheng, Xiaoqing Wan, Guofu Zhu
    BMC Complementary and Alternative Medicine.2017;[Epub]     CrossRef
  • The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
    Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, Hendrina Shipanga, Daniella Munro, Mohammad A. M. Al Mazeedi, Hashim A. M. Almazyadi, Karlien Kallmeyer, Collet Dandara, Michael S. Pepper, M. Iqbal Parker, Kevin Dzobo
    International Journal of Molecular Sciences.2017; 18(7): 1586.     CrossRef
  • Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
    Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
    Scientific Reports.2017;[Epub]     CrossRef
  • Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
    Henrik Nienhüser, Thomas Schmidt
    International Journal of Molecular Sciences.2017; 19(1): 43.     CrossRef
  • 17,225 View
  • 922 Download
  • 46 Web of Science
  • 41 Crossref
Close layer
Original Article
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Dae Ho Lee, Jung Shin Lee, Jie Wang, Te-Chun Hsia, Xin Wang, Jongseok Kim, Mauro Orlando
Cancer Res Treat. 2015;47(4):616-629.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.051
AbstractAbstract PDFPubReaderePub
Purpose
This subgroup analysis of a phase II trial was conducted to assess possible ethnicity-based trends in efficacy and safety in East Asian (EA) and non-EA populations with nonsquamous non-small cell lung cancer (NSCLC).
Materials and Methods
Never-smoker patients (n=240) with locally advanced or metastatic nonsquamous NSCLC included 133 EA patients randomized to pemetrexed supplemented with dexamethasone, folic acid, and vitamin B12 plus erlotinib (pemetrexed-erlotinib) (n=41), erlotinib (n=49), or pemetrexed (n=43), and 107 non-EA patients randomized to pemetrexed-erlotinib (n=37), erlotinib (n=33), or pemetrexed (n=37). The primary endpoint, progression-free survival (PFS), was analyzed using a multivariate Cox model.
Results
Consistent with the results of the overall study, a statistically significant difference in PFS among the three arms was noted in the EA population favoring pemetrexed-erlotinib (overall p=0.003) as compared with either single-agent arm (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29 to 0.79; p=0.004 vs. erlotinib; HR, 0.40; 95% CI, 0.23 to 0.70; p=0.001 vs. pemetrexed). The EA patients treated with pemetrexed-erlotinib achieved a longer median PFS (7.4 months) compared with erlotinib (4.5 months) and pemetrexed (4.0 months). The PFS results also numerically favored pemetrexed-erlotinib in the non-EA population (overall p=0.210) (HR, 0.62; 95% CI, 0.37 to 1.05; p=0.078 vs. erlotinib; HR, 0.75; 95% CI, 0.42 to 1.32; p=0.320 vs. pemetrexed) (median PFS: pemetrexed-erlotinib, 6.7 months; erlotinib, 3.0 months; pemetrexed, 4.4 months).
Conclusion
The PFS results from this subset analysis in both EA and non-EA populations are consistent with the results in the overall population. The PFS advantage for pemetrexed-erlotinib is significant compared with the single agents in EA patients.

Citations

Citations to this article as recorded by  
  • Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
    Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition
    Elisabeth Smolle, Martin Pichler
    Cancers.2019; 11(2): 204.     CrossRef
  • Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
    Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
    Pteridines.2019; 30(1): 171.     CrossRef
  • A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
    James Chih-Hsin Yang, Tony Mok, Baohui Han, Mauro Orlando, Tarun Puri, Keunchil Park
    Clinical Lung Cancer.2018; 19(1): 27.     CrossRef
  • Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
    Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim Gucalp, Missak Haigentz, Venu G. Bathini, Huiyu Wen, Kaili Zhou, Patricia B. Pasquinelli, Srikanth Gajavelli, Meera Sreedhara, Xianhong Xie, Primo N. Lara, David R. Gandara,
    Clinical Lung Cancer.2017; 18(1): 60.     CrossRef
  • Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)
    Haihong Yang, Qiuhua Deng, Yuan Qiu, Jun Huang, Yubao Guan, Fengnan Wang, Xin Xu, Xinyun Yang
    ESMO Open.2017; 2: e000112.     CrossRef
  • Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure
    Jung Ran Choi, Seong Yong Park, O Kyu Noh, Young Wha Koh, Dae Ryong Kang
    Annals of Occupational and Environmental Medicine.2016;[Epub]     CrossRef
  • Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
    Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
    Cancer Research and Treatment.2015; 47(4): 549.     CrossRef
  • 12,711 View
  • 137 Download
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP